Try our Advanced Search for more refined results

IN RE: AVANDIA MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION

  1. May 16, 2014

    GlaxoSmithKline Gets 115 Avandia Injury Cases Dismissed

    A Pennsylvania district judge dismissed 115 out of 117 cases that GlaxoSmithKline LLC argued were outside the statute of limitations in the multidistrict litigation over injuries caused by diabetes drug Avandia, ruling Friday that the cases were clearly untimely.

  2. February 26, 2014

    GSK Can't Shake Calif. County's Avandia False Ad Claims

    A Pennsylvania federal judge on Tuesday denied GlaxoSmithKline PLC's bid to partially dismiss false advertising claims brought by Santa Clara County, Calif., over GSK's diabetes medication Avandia, rejecting its argument that the claims must be based on false advertising displayed within the county.

  3. October 24, 2013

    GSK Can't Sink Avandia Prescription Coverage RICO Suits

    GlaxoSmithKline LLC failed Wednesday to escape a trio of racketeering class actions in Pennsylvania federal court alleging its concealment of heart risks associated with the diabetes drug Avandia conned health benefit payors into covering pricey prescriptions.

  4. January 22, 2013

    Attys Agree To $143M Fee Split In $2.3B Avandia MDL

    Plaintiffs' attorneys on Thursday filed a plan in Pennsylvania federal court to split $143 million to resolve a fee dispute in what could be a $2.3 billion settlement in a massive multidistrict litigation over GlaxoSmithKline PLC's alleged failure to warn consumers about health risks related to its diabetes drug Avandia.

  5. September 17, 2012

    Avandia Heart Attack Plaintiffs Want Suits Out Of MDL

    A group of plaintiffs urged a Pennsylvania federal judge on Thursday to endorse the transfer of their suits claiming the GlaxoSmithKline PLC diabetes drug Avandia caused heart attacks from multidistrict litigation to the courts where they were filed, arguing the MDL had run its course.

  6. August 29, 2012

    MDL Plaintiffs Say GSK Won't Uphold Avandia Settlement

    A group of 239 plaintiffs in multidistrict litigation for heart disease claims against GlaxoSmithKline PLC over diabetes drug Avandia asked a Pennsylvania federal judge to disburse the remaining funds from their settlement agreement, saying the pharma giant refuses to release the money.

  7. April 06, 2012

    2 Cases Remanded To State Court From GSK Avandia MDL

    A federal judge on Wednesday sent two cases back to state court from a multidistrict litigation against GlaxoSmithKline PLC for alleged Medicaid fraud related to its diabetes drug Avandia, saying there weren't enough significant federal issues to justify keeping the cases in federal court.

  8. January 17, 2012

    GSK Settles Bulk Of Avandia MDL Cases

    GlaxoSmithKline PLC has settled a majority of state cases and multidistrict litigation cases over its alleged failure to warn consumers about health risks related to diabetes drug Avandia, which has been linked to increased occurrences of heart attack and stroke, the company said Tuesday.

  9. November 08, 2011

    GSK Prodded Toward Mediation In Avandia MDL

    Less than a week after GlaxoSmithKline PLC paid $3 billion to settle U.S. government probes into, among other practices, its marketing of Avandia, a Pennsylvania federal judge on Monday pushed the drugmaker toward mediation with plaintiffs in multidistrict litigation over the controversial diabetes drug.

  10. October 28, 2011

    County Can't Pursue Own Avandia False Ad Claims: Judge

    A Pennsylvania federal judge ruled Wednesday that a California county can't personally pursue a false advertising suit in multidistrict litigation over GlaxoSmithKline PLC's alleged concealment of the risks of diabetes medication Avandia, but that it can assert the claims on behalf of state residents.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!